TP53 and acute myeloid leukemia: Given the increased co‐occurrence of TP53 mutations with these other cytogenetic abnormalities associated with an increased risk of relapse, we performed a Cox regression analysis to determine the independent risk of TP53 mutations in patients with AML following an allo‐SCT (Table 2).